Archives of Industrial Biotechnology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (629)348-3199

Rapid Communication - Archives of Industrial Biotechnology (2023) Volume 7, Issue 6

Polymers in medicine: From drug delivery systems to tissue engineering

Micaela Tosi*

Department of Biotechnology, University of Berne, Switzerland

*Corresponding Author:
Micaela Tosi
Department of Biotechnology
University of Berne
Switzerland
E-mail:micaelatosi@gmail.com

Received: 22-Nov-2023, Manuscript No. AAAIB-23-144511; Editor assigned: 24-Nov-2023, PreQC No. AAAIB-23-144511 (PQ); Reviewed: 06-Dec-2023, QC No. AAAIB-23-144511; Revised: 20-Dec-2023, Manuscript No. AAAIB-23-144511 (R); Published: 28-Dec-2023, DOI: 10.35841/aaaib- 7.6.181

Citation: Tosi M. Polymers in medicine: From drug delivery systems to tissue engineering. Arch Ind Biot. 2023; 7(6):181

Visit for more related articles at Archives of Industrial Biotechnology

Polymers have revolutionized various fields, and medicine is no exception. Their versatility and ability to be tailored for specific applications have led to significant advancements in medical technology. Among the most transformative uses of polymers in medicine are drug delivery systems and tissue engineering. These applications leverage the unique properties of polymers to improve therapeutic outcomes, enhance patient care, and enable innovative treatments [1], [2]

Polymers can be engineered to release drugs gradually over time, providing sustained therapeutic effects and reducing the frequency of dosing. This is particularly beneficial for drugs with short half-lives or those requiring constant levels in the bloodstream. By modifying polymer properties or attaching targeting moieties, drugs can be delivered specifically to disease sites, minimizing side effects and improving efficacy. This is particularly useful in treating cancer, where polymer-based carriers can target tumor cells while sparing healthy tissue. Polymers used in drug delivery are often biocompatible and biodegradable, reducing the risk of adverse reactions and eliminating the need for surgical removal once the drug has been delivered. Various polymer-based drug delivery systems have been developed, including liposomes, micelles, and nanoparticles. For instance, poly(lactic-co-glycolic acid) (PLGA) is a commonly used polymer in controlled-release formulations due to its biocompatibility and biodegradability [3].

Polymers provide structural support for growing cells and tissues. Scaffolds made from polymers can be designed to mimic the extracellular matrix, providing a suitable environment for cell adhesion, proliferation, and differentiation. Polymers can be tailored to meet specific needs, such as altering their mechanical properties, degradation rates, and bioactivity. This customization allows for the creation of scaffolds that closely match the properties of the tissue being repaired or replaced. Biodegradable polymers are used to create temporary scaffolds that gradually degrade as new tissue forms. This eliminates the need for scaffold removal and supports the natural healing process. Common polymers used in tissue engineering include collagen, polyglycolic acid (PGA), and polycaprolactone (PCL). These materials have been used to develop scaffolds for a variety of tissues, including skin, bone, and cartilage [4], [5]

Designing polymers with specific properties for drug delivery and tissue engineering requires a deep understanding of both material science and biological interactions. This complexity can lead to difficulties in optimizing performance and ensuring safety. Ensuring that polymer-based products are safe and effective requires rigorous testing and adherence to regulatory standards. The process can be time-consuming and costly. Achieving seamless integration of polymer-based systems with biological tissues remains a challenge. Issues such as immune responses and long-term biocompatibility need to be addressed [6], [7]

Looking ahead, research is focused on developing more advanced polymers with improved properties and functionality. Innovations in nanotechnology, bioengineering, and materials science are expected to drive the next generation of polymer-based medical applications, leading to more effective treatments and improved patient outcomes [8], [9]

Polymers have made significant contributions to medicine, particularly in drug delivery systems and tissue engineering. Their ability to be tailored for specific applications has led to advancements that enhance therapeutic efficacy and support tissue regeneration. While challenges remain, ongoing research and development hold promise for further innovations, paving the way for new treatments and improved patient care. By harnessing the potential of polymers, the future of medicine looks increasingly promising, with opportunities for enhanced drug delivery, personalized therapies, and advanced tissue engineering solutions [10].

References

  1. Carole TM, Pellegrino J, Paster MD. Opportunities in the industrial biobased products industry. In Proceedings of the Twenty-Fifth Symposium on Biotechnology for Fuels and Chemicals.2003, Breckenridge, CO 2004.Humana Press. Appl Biochem Biotechnol.2004 Spring;113-116:871-85.

    2. Indexed at , Google Scholar , Cross Ref

  2. Erickson B, Nelson, Winters P. Perspective on opportunities in industrial biotechnology in renewable chemicals. J Biotechnol. 2012;7(2):176-85.

    3. Indexed at , Google Scholar , Cross Ref

  3. Hermann BG, Blok K, Patel MK. Producing bio-based bulk chemicals using industrial biotechnology saves energy and combats climate change. Environ Sci Technol.2007;41(22):7915-21.

    4. Indexed at , Google Scholar , Cross Ref

  4. Dornburg V, Hermann BG, Patel MK. Scenario projections for future market potentials of biobased bulk chemicals. Environ Sci Technol.2008;42(7):2261-7.

    5. Indexed at , Google Scholar , Cross Ref

  5. Xu Y, Isom L, Hanna MA. Adding value to carbon dioxide from ethanol fermentations. Bioresour Technol. 2010;101(10):3311-9.

    6. Indexed at , Google Scholar , Cross Ref

  6. Johnson IS. The trials and tribulations of producing the first genetically engineered drug. Nat Rev Drug Discov. 2003;2(9):747-51.

    7. Indexed at , Google Scholar , Cross Ref

  7. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Human Gene Therapy. 2005;16(9):1016-27.

    8. Indexed at , Google Scholar , Cross Ref

  8. Chen S, Yu L, Jiang C, et al. Pivotal study of iodine-131–labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol.2005;23(7):1538-47.

    9. Indexed at , Google Scholar , Cross Ref

  9. Crombet T, Osorio M, Cruz T, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol. 2004;22(9):1646-54.

    10. Indexed at , Google Scholar , Cross Ref

  10. Bao GQ, Li Y, Ma QJ, et al. Isolating human antibody against human hepatocellular carcinoma by guided-selection. Cancer Biol 2005;4(12):1374-80.

    11. Indexed at , Google Scholar , Cross Ref

Get the App